 | • レポートコード：MRC2312MG08540 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、84ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場規模と予測を収録しています。・世界の長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場：売上、2018年-2023年、2024年-2029年 ・世界の長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「エポエチン-アルファ」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 長時間作用型遺伝子組換えヒトエリスロポエチン製剤のグローバル主要企業は、Amgen、 Johnson & Johnson、 Kyowa Kirinなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、長時間作用型遺伝子組換えヒトエリスロポエチン製剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場：タイプ別、2018年-2023年、2024年-2029年 世界の長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場：タイプ別市場シェア、2022年 ・エポエチン-アルファ、エポエチン-ベータ、ダルベポエチン-アルファ、その他 世界の長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場：用途別、2018年-2023年、2024年-2029年 世界の長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場：用途別市場シェア、2022年 ・貧血、腎臓病、その他 世界の長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場：地域・国別、2018年-2023年、2024年-2029年 世界の長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における長時間作用型遺伝子組換えヒトエリスロポエチン製剤のグローバル売上、2018年-2023年 ・主要企業における長時間作用型遺伝子組換えヒトエリスロポエチン製剤のグローバル売上シェア、2022年 ・主要企業における長時間作用型遺伝子組換えヒトエリスロポエチン製剤のグローバル販売量、2018年-2023年 ・主要企業における長時間作用型遺伝子組換えヒトエリスロポエチン製剤のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Amgen、 Johnson & Johnson、 Kyowa Kirin ************************************************************* ・調査・分析レポートの概要 長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場の定義 市場セグメント 世界の長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場規模 世界の長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場規模：2022年 VS 2029年 世界の長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの長時間作用型遺伝子組換えヒトエリスロポエチン製剤の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の長時間作用型遺伝子組換えヒトエリスロポエチン製剤製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：エポエチン-アルファ、エポエチン-ベータ、ダルベポエチン-アルファ、その他 長時間作用型遺伝子組換えヒトエリスロポエチン製剤のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：貧血、腎臓病、その他 長時間作用型遺伝子組換えヒトエリスロポエチン製剤の用途別グローバル売上・予測 ・地域別市場分析 地域別長時間作用型遺伝子組換えヒトエリスロポエチン製剤市場規模 2022年と2029年 地域別長時間作用型遺伝子組換えヒトエリスロポエチン製剤売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Amgen、 Johnson & Johnson、 Kyowa Kirin ... |
This research report provides a comprehensive analysis of the Long-acting Recombinant Human Erythropoietin Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Long-acting Recombinant Human Erythropoietin Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Long-acting Recombinant Human Erythropoietin Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Long-acting Recombinant Human Erythropoietin Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Long-acting Recombinant Human Erythropoietin Drugs market presents opportunities for various stakeholders, including Anemia, Kidney Disorders. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Long-acting Recombinant Human Erythropoietin Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Long-acting Recombinant Human Erythropoietin Drugs market was valued at US$ 795.1 million in 2022 and is projected to reach US$ 1052.8 million by 2029, at a CAGR of 4.4% during the forecast period.
Key Features:
The research report on the Long-acting Recombinant Human Erythropoietin Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Long-acting Recombinant Human Erythropoietin Drugs market.
Market Overview: The report provides a comprehensive overview of the Long-acting Recombinant Human Erythropoietin Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Epoetin-alfa, Epoetin-beta), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Long-acting Recombinant Human Erythropoietin Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Long-acting Recombinant Human Erythropoietin Drugs market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Long-acting Recombinant Human Erythropoietin Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Long-acting Recombinant Human Erythropoietin Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Long-acting Recombinant Human Erythropoietin Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Long-acting Recombinant Human Erythropoietin Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Long-acting Recombinant Human Erythropoietin Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Long-acting Recombinant Human Erythropoietin Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Long-acting Recombinant Human Erythropoietin Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
Market segment by Application
Anemia
Kidney Disorders
Others
Global Long-acting Recombinant Human Erythropoietin Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Amgen
Johnson & Johnson
Kyowa Kirin
Outline of Major Chapters:
Chapter 1: Introduces the definition of Long-acting Recombinant Human Erythropoietin Drugs, market overview.
Chapter 2: Global Long-acting Recombinant Human Erythropoietin Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Long-acting Recombinant Human Erythropoietin Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Long-acting Recombinant Human Erythropoietin Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Long-acting Recombinant Human Erythropoietin Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Long-acting Recombinant Human Erythropoietin Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Long-acting Recombinant Human Erythropoietin Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Long-acting Recombinant Human Erythropoietin Drugs Overall Market Size
2.1 Global Long-acting Recombinant Human Erythropoietin Drugs Market Size: 2022 VS 2029
2.2 Global Long-acting Recombinant Human Erythropoietin Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Long-acting Recombinant Human Erythropoietin Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Long-acting Recombinant Human Erythropoietin Drugs Players in Global Market
3.2 Top Global Long-acting Recombinant Human Erythropoietin Drugs Companies Ranked by Revenue
3.3 Global Long-acting Recombinant Human Erythropoietin Drugs Revenue by Companies
3.4 Global Long-acting Recombinant Human Erythropoietin Drugs Sales by Companies
3.5 Global Long-acting Recombinant Human Erythropoietin Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Long-acting Recombinant Human Erythropoietin Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Long-acting Recombinant Human Erythropoietin Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Long-acting Recombinant Human Erythropoietin Drugs Players in Global Market
3.8.1 List of Global Tier 1 Long-acting Recombinant Human Erythropoietin Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Long-acting Recombinant Human Erythropoietin Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Long-acting Recombinant Human Erythropoietin Drugs Market Size Markets, 2022 & 2029
4.1.2 Epoetin-alfa
4.1.3 Epoetin-beta
4.1.4 Darbepoetin-alfa
4.1.5 Others
4.2 By Type – Global Long-acting Recombinant Human Erythropoietin Drugs Revenue & Forecasts
4.2.1 By Type – Global Long-acting Recombinant Human Erythropoietin Drugs Revenue, 2018-2023
4.2.2 By Type – Global Long-acting Recombinant Human Erythropoietin Drugs Revenue, 2024-2029
4.2.3 By Type – Global Long-acting Recombinant Human Erythropoietin Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Long-acting Recombinant Human Erythropoietin Drugs Sales & Forecasts
4.3.1 By Type – Global Long-acting Recombinant Human Erythropoietin Drugs Sales, 2018-2023
4.3.2 By Type – Global Long-acting Recombinant Human Erythropoietin Drugs Sales, 2024-2029
4.3.3 By Type – Global Long-acting Recombinant Human Erythropoietin Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Long-acting Recombinant Human Erythropoietin Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2022 & 2029
5.1.2 Anemia
5.1.3 Kidney Disorders
5.1.4 Others
5.2 By Application – Global Long-acting Recombinant Human Erythropoietin Drugs Revenue & Forecasts
5.2.1 By Application – Global Long-acting Recombinant Human Erythropoietin Drugs Revenue, 2018-2023
5.2.2 By Application – Global Long-acting Recombinant Human Erythropoietin Drugs Revenue, 2024-2029
5.2.3 By Application – Global Long-acting Recombinant Human Erythropoietin Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Long-acting Recombinant Human Erythropoietin Drugs Sales & Forecasts
5.3.1 By Application – Global Long-acting Recombinant Human Erythropoietin Drugs Sales, 2018-2023
5.3.2 By Application – Global Long-acting Recombinant Human Erythropoietin Drugs Sales, 2024-2029
5.3.3 By Application – Global Long-acting Recombinant Human Erythropoietin Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Long-acting Recombinant Human Erythropoietin Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2022 & 2029
6.2 By Region – Global Long-acting Recombinant Human Erythropoietin Drugs Revenue & Forecasts
6.2.1 By Region – Global Long-acting Recombinant Human Erythropoietin Drugs Revenue, 2018-2023
6.2.2 By Region – Global Long-acting Recombinant Human Erythropoietin Drugs Revenue, 2024-2029
6.2.3 By Region – Global Long-acting Recombinant Human Erythropoietin Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Long-acting Recombinant Human Erythropoietin Drugs Sales & Forecasts
6.3.1 By Region – Global Long-acting Recombinant Human Erythropoietin Drugs Sales, 2018-2023
6.3.2 By Region – Global Long-acting Recombinant Human Erythropoietin Drugs Sales, 2024-2029
6.3.3 By Region – Global Long-acting Recombinant Human Erythropoietin Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Long-acting Recombinant Human Erythropoietin Drugs Revenue, 2018-2029
6.4.2 By Country – North America Long-acting Recombinant Human Erythropoietin Drugs Sales, 2018-2029
6.4.3 US Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.4.4 Canada Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.4.5 Mexico Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Long-acting Recombinant Human Erythropoietin Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Long-acting Recombinant Human Erythropoietin Drugs Sales, 2018-2029
6.5.3 Germany Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.5.4 France Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.5.5 U.K. Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.5.6 Italy Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.5.7 Russia Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.5.9 Benelux Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Long-acting Recombinant Human Erythropoietin Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Long-acting Recombinant Human Erythropoietin Drugs Sales, 2018-2029
6.6.3 China Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.6.4 Japan Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.6.5 South Korea Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.6.7 India Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Long-acting Recombinant Human Erythropoietin Drugs Revenue, 2018-2029
6.7.2 By Country – South America Long-acting Recombinant Human Erythropoietin Drugs Sales, 2018-2029
6.7.3 Brazil Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.7.4 Argentina Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Long-acting Recombinant Human Erythropoietin Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Long-acting Recombinant Human Erythropoietin Drugs Sales, 2018-2029
6.8.3 Turkey Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.8.4 Israel Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
6.8.6 UAE Long-acting Recombinant Human Erythropoietin Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Amgen
7.1.1 Amgen Company Summary
7.1.2 Amgen Business Overview
7.1.3 Amgen Long-acting Recombinant Human Erythropoietin Drugs Major Product Offerings
7.1.4 Amgen Long-acting Recombinant Human Erythropoietin Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Amgen Key News & Latest Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Company Summary
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Long-acting Recombinant Human Erythropoietin Drugs Major Product Offerings
7.2.4 Johnson & Johnson Long-acting Recombinant Human Erythropoietin Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Johnson & Johnson Key News & Latest Developments
7.3 Kyowa Kirin
7.3.1 Kyowa Kirin Company Summary
7.3.2 Kyowa Kirin Business Overview
7.3.3 Kyowa Kirin Long-acting Recombinant Human Erythropoietin Drugs Major Product Offerings
7.3.4 Kyowa Kirin Long-acting Recombinant Human Erythropoietin Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Kyowa Kirin Key News & Latest Developments
8 Global Long-acting Recombinant Human Erythropoietin Drugs Production Capacity, Analysis
8.1 Global Long-acting Recombinant Human Erythropoietin Drugs Production Capacity, 2018-2029
8.2 Long-acting Recombinant Human Erythropoietin Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Long-acting Recombinant Human Erythropoietin Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Long-acting Recombinant Human Erythropoietin Drugs Supply Chain Analysis
10.1 Long-acting Recombinant Human Erythropoietin Drugs Industry Value Chain
10.2 Long-acting Recombinant Human Erythropoietin Drugs Upstream Market
10.3 Long-acting Recombinant Human Erythropoietin Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Long-acting Recombinant Human Erythropoietin Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer